Deep Intelligence Across Industries

Himadri Speciality Chemical is India's largest coal-tar distiller and dominant domestic producer of coal tar pitch — the binder used in aluminium smelting and graphite electrodes — with ~70% domestic market share and a 500,000 MTPA distillation base. On that integrated carbon backbone it has built a fast-growing speciality carbon black franchise (130,000 MTPA speciality capacity within 250,000 MTPA total carbon black) that management says places it among the top five global speciality carbon black producers, operating from Mahistikry, West Bengal — described as the world's largest single-location speciality carbon black site. The company is now pivoting toward "advanced materials": LFP cathode active material, anode materials, silicon-carbon anode technology (via Sicona), carbon nanotubes, super-speciality carbon black, and high-value coal-tar derivatives such as anthraquinone and carbazole. Through the Birla Tyres turnaround it has also entered tyre manufacturing. FY26 delivered record PAT of ₹755 crore at a ~21% EBITDA margin, with a net cash balance sheet. --- ### What the company does Himadri is a vertically integrated carbon-chemistry company. Its core feedstock is coal tar — a by-product of metallurgical coke ovens operated by steel producers. Himadri distils coal tar into a family of fractions and converts them into a portfolio of downstream products: **Coal tar pitch (CTP):** the heaviest fraction, sold as binder pitch to aluminium smelters (for anodes) and graphite electrode manufacturers, and increasingly into battery anode precursors and specialty carbons. Himadri is India's largest CTP producer with roughly 70% market share (company description reproduced by Revelio Labs). It also sells liquid CTP for export; in Q3 FY26 it commissioned a Mangalore port terminal and shipped 3,600 tonnes of liquid CTP to the Middle East (Q3 FY26 earnings call transcript, 21 January 2026). **Carbon black:** produced from carbon black feedstock oil (a coal-tar fraction), sold as rubber-grade carbon black to tyre and mechanical rubber goods makers and as speciality carbon black to plastics, inks, paints, coatings, and conductive/battery applications. **Naphthalene and derivatives:** refined/high-purity naphthalene, naphthalene balls, and SNF (sulphonated naphthalene formaldehyde) and PCE superplasticisers for construction chemicals and agrochemical/dye intermediates. Screener describes the company as the largest player in naphthalene and SNF in India. **Speciality oils:** creosote and other oils for wood preservation, carbon black feedstock, and industrial uses. **Advanced coal-tar derivatives (new):** anthraquinone, carbazole and fluorene, being manufactured for the first time in India through forward integration of existing distillates. **Battery / new-energy materials (new):** LFP cathode active material, anode materials (initial 200 MTPA plant inaugurated April 2026), and silicon-carbon anode technology licensed from Sicona. **Advanced carbon (new):** carbon nanotubes (indigenous technology; 200 MTPA plant planned) and super-speciality carbon black. **Tyres (new):** through Birla Tyres (off-highway/OHT, passenger, commercial vehicle, EV, and agricultural tyres), restarted after insolvency acquisition. **Clean power:** captive/co-generation power from carbon black tail gas, reported as a separate "Power" segment. **Other:** logistics and a consumer business ("Durofresh") referenced in FY27 growth commentary (Autocar Pro, May 2026). ### Business and revenue model Revenue is overwhelmingly product sales (B2B industrial chemicals and materials sold on contract and spot basis). There is no material service, subscription, or licensing revenue disclosed; Himadri is a licensee (of Sicona's silicon-carbon anode technology), not a licensor. Pricing in the legacy businesses is largely cost-plus/pass-through: carbon black and CTP prices typically track feedstock (coal tar, carbon black feedstock oil) with a lag, so reported revenue can fall even as margins rise — exactly the FY26 pattern, when revenue grew only ~1% while PAT rose 36% because raw material prices fell and mix shifted toward speciality grades. ### Value chain position Himadri sits in the mid-stream conversion layer of the carbon value chain: upstream are steel companies' coke ovens (coal tar suppliers) and refiners; downstream are aluminium smelters, graphite electrode makers, tyre makers, plastics compounders, ink/paint formulators, construction chemical firms, and (prospectively) lithium-ion cell manufacturers. Its strategic thrust is to move further downstream and up the value curve — from bulk pitch and rubber black into speciality black, battery materials, and finished tyres. ### Customer types and end-markets Per company and ICRA descriptions, end-markets include aluminium, graphite electrodes, tyres, mechanical rubber goods, plastics, inks, paints and coatings, dyes, agrochemicals, defence, construction chemicals, and lithium-ion batteries. Geographically, exports were 26.79% and domestic sales 73.21% of revenue in FY25 (Sustainability Report FY24-25, filed 17 December 2025). ### Company self-description vs. independent characterisation The company describes itself as "a global speciality chemical conglomerate with a strong focus on research and development, innovation and sustainability" (FY26 press release), and in Q1 FY27 commentary as working toward becoming a global advanced-materials and application-driven solutions company. PTI's newswire characterised it as a "clean-tech company" (April 2026). **Independent characterisation:** Economically, Himadri remains today a coal-tar distillation and carbon black company whose earnings are dominated by its Carbon Materials & Chemicals segment (₹1,278.90 crore of Q1 FY27 revenue). The "advanced materials" narrative is real in terms of capital commitment and R&D, but the battery, CNT and anode businesses are pre-revenue or at pilot/initial scale (200 MTPA anode; 2,000 MTPA LFP targeted for Q3 FY27 versus a 200,000 MTPA long-term vision). The investment case therefore rests on (a) continued margin expansion from speciality carbon black and value-added derivatives, which is proven, and (b) option value on battery materials, which is unproven at commercial scale.

Company Headquarters: London, UK Founded: 2011 Workforce: ~1,475 Company Working: Orion Engineered Carbons SA is a leading global manufacturer & supplier of carbon black, a solid form of carbon manufactured as pellets or powder. The company has two business segments: rubber carbon black and specialty carbon black. It offers specialty carbon black for various applications in coating systems, polymers, printing systems, and special applications such as battery, ceramics, foundry, non-woven, and graphite molded parts. It has four innovative centers in three regions: Europe, North America, and Asia-Pacific. Also, it has 14 manufacturing facilities present worldwide. The company has a major presence in Germany, the United States, South Korea, China, Brazil, and South Africa, and Germany holds the dominant market share in terms of revenue.

Kaneka is a mid-cap Japanese diversified chemical company. Over the past decade it has been reshaping itself from a commodity-heavy vinyls, foams and fibres producer into what management calls a "Life Focus" solutions company. FY2026 sales were a record ¥811.6bn. They are spread across four reportable units: - Material Solutions (PVC, modifiers, MS polymer, the biodegradable polymer Green Planet™) - Quality of Life Solutions (polyimide films, PV, foams, modacrylic fibres) - Health Care Solutions (blood-purification devices, catheters, neuro-coils, pharma CDMO) - Nutrition Solutions (Kaneka Ubiquinol™, probiotics, margarine/yeast/dairy) Kaneka is a global leader in several niche chemistries: MBS/acrylic impact modifiers, silyl-terminated polyether (MS Polymer™), reduced coenzyme Q10, and modacrylic hair fibre. Profitability is structurally low, with a 4.1% operating margin in FY2026 and a 6.4% ROE. The stock traded at a P/B of about 0.7x in September 2026. Management's 2026 plan targets ¥68bn operating income and 10% ROE by FY2029 (Kaneka "FY2028"). It relies on Medical, E&I and supplement growth, plus aggressive capital-efficiency measures. --- ### What Kaneka does Kaneka makes and sells a broad portfolio of chemical, materials, medical, pharmaceutical and food products. It organises them into ten "Solutions Vehicles" (SVs), grouped into four "Solutions Units" (SUs), which are the reportable segments. Per the FY2026 Tanshin segment note, each SU sets a single global strategy and runs Japanese and overseas subsidiaries as one business. **Company's own description (paraphrased from the FY2026 Tanshin segment note):** **Material SU:** supplies high-performance materials for social infrastructure and lighter, more fuel-efficient mobility, plus advanced materials such as biodegradable polymers that serve environmental goals. **Quality of Life SU:** supplies materials and services for energy saving and smart housing and infrastructure, and serves the IoT/AI information economy. **Health Care SU:** combines devices and pharmaceuticals for medicine, health and nursing care. It is building businesses in biopharmaceuticals and regenerative/cell medicine. **Nutrition SU:** supplies distinctive food materials and supplements for diverse diets and health. It also supports agriculture, livestock and fisheries production. **Corporate purpose framing (Three-Year Initiatives 2026).** The corporate purpose is "KANEKA thinks 'Wellness First'". Its supporting pillars are Life Focus Management, Human-Driven Management, R2B+P ("Research to Business + Production") and "Think Global, Act Local". Management defines "life science" broadly. It covers biomanufacturing (Green Planet™, genome editing, fermentation), biopharma, regenerative medicine, supplements, organic dairy, PV and medical devices — all presented as serving "life on Earth". ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue type | Almost entirely product sales (B2B materials, devices, ingredients, foods). Contract manufacturing (CDMO) revenue sits within Pharma. Kaneka does not disclose any subscription or licensing revenue line; licensing income is not separately reported | | Product vs. service mix | Not disclosed. Kaneka's independent assessment is that product sales are more than 95% of revenue; services are limited to construction-method/PV installation-related services in QOL and CDMO services in Pharma | | Value-chain position | Mid-stream: intermediates, specialty polymers and additives. Downstream: finished medical devices, PV modules, consumer-facing supplements and dairy products. Upstream exposure through chlor-alkali/PVC (naphtha, salt, power) | | Customer types | Industrial compounders and converters (PVC, adhesives/sealants, automotive), electronics makers (FPC/smartphone, TV), housing builders, hospitals and distributors (medical devices), pharma companies (CDMO/API), supplement brands, food manufacturers and bakeries, agricultural users | | End-markets | Construction and housing; automotive and mobility; electronics/ICT (smartphones, AI-related high-frequency); renewable energy; healthcare (cardiology, nephrology/apheresis, neurovascular, GI endoscopy); pharma; dietary supplements; bakery and food; agriculture | | Geographic mix (FY2026) | Japan 55.2%, Asia 20.1%, Europe 10.3%, North America 9.2%, Other 5.2% (FY2026 Tanshin) | ### "Leading-edge" vs "Foundation" portfolio lens Management splits the portfolio into two groups (Three-Year Initiatives 2026): **Leading-edge businesses:** Modified Silicone polymers (MS), E&I Technology, PV & Energy management, Medical, Pharma, and Supplemental Nutrition. **Foundation businesses:** Vinyls & Chlor-Alkali, Modifiers (MOD), Foam & Residential Techs, Performance Fibers, and Foods & Agris. Leading-edge businesses supplied 53% of operating income in FY2026, up from 48% in FY2025. The target is 56% in FY2027 and 62% by FY2029. The 2026 plan also puts Green Planet™ and genome editing in the life-science growth pool. ### Independent characterisation Kaneka is best understood as a portfolio of ten mid-sized niche businesses sitting on a cyclical commodity base. About 40% of revenue (Material SU) is exposed to Asian PVC pricing and Western construction demand. That base has driven most of the earnings volatility seen in FY2026. The value-creation engine lies elsewhere: **Medical devices:** the Health Care SU earned a 17.9% segment margin in FY2026. **E&I polyimide films:** these benefit from AI-driven high-frequency demand. **Global ubiquinol franchise:** The central investment question is whether these businesses can scale fast enough to lift group margins from about 4% toward the 7.3% FY2029 target. A secondary question is whether that can happen before the corporate cost burden absorbs the gains: unallocated corporate expenses (mainly basic R&D) were ¥39.1bn in FY2026, larger than total group operating income.

Company Headquarters: Feusisberg, Switzerland Founded: 1890 Workforce: ~ 92,511 Company Working: Kuehne + Nagel Inc. (Kuehne+Nagel) is one of the world’s leading transportation and logistics companies. Its strong market position lies in sea logistics, air logistics, road logistics, and contract logistics, with a clear focus on integrated logistics solutions. Sea logistics has generally been the most profitable portion of the firm, accounting for about 42.7% of total revenue in 2021. The company's mission is to become a more balanced, fully integrated freight forwarder while strengthening its end-to-end offering to clients.

Company Headquarters: Selangor, Malaysia Founded: 1988 Workforce: ~3,000 Company Working: Karex Berhad is the world’s largest condom and lubricant manufacturer. The company has operations across the UK, US, Malaysia, and Thailand. It has clientele, including NGOs, governments, and brand owners, and retails in more than 130 countries across the globe. Karex Berhad has operations in the Americas, Asia, Europe, and Africa. It manufactures condoms with numerous colors, textures, and properties.

Company Headquarters: Würzburg, Germany Founded: 2001 Workforce: ~597 Company Working: va-Q-tec AG is one of the leading technology suppliers of highly efficient products and solutions in thermal insulation. The company provides customers from a wide range of industries with high-performance insulation solutions that enable the customer to increase their energy efficiency significantly. It operates in four segments: products, systems, services, and others. These are applied in various industries such as thermo-logistics, refrigeration & food industry, industrial & technical applications such as water boilers, construction industry, and mobility area. The product segment develops, produces, and markets innovative vacuum insulation panels (VIPs) and phase change materials (PCMs). The company manufactures passive thermal packaging, containers, and boxes in the system segment by combining VIPs and PCMs. In the service segment, the company operates a fleet of rental containers that produce themselves and allow temperature-sensitive transports to be operated securely and cost-efficiently compared with actively cooled containers. It has a presence over Kölleda, Switzerland, the UK, Korea, the US, Japan, Latin America, and Singapore.

Company Headquarters: Illinois, US Founded: 1946 Workforce: ~1,001 Company Working: Sonoco ThermoSafe is the leading global provider of temperature assurance packaging for the safe and efficient transport of pharmaceuticals, biologics, vaccines, and other temperature-sensitive products. The company provides refrigerated, frozen, or controlled room temperature applications. Sonoco ThermoSafe's ISC Labs enable designing and testing services with innovative packaging solutions and standard services. It operates in the Americas, Europe, and Asia-Pacific.

Company Headquarters: Delhi, India Founded: 1991 Workforce: ~18000 Company Working: Mankind Pharma (Mankind) is a leading pharmaceutical company. The company manufactures products for antibiotics, gastrointestinal, cardiovascular, dermal, erectile dysfunction medications, and sexual wellness. The company operates in more than 34 countries including Asia, Africa, South-East Asia, Gulf countries and CIS countries. Moreover, the company specializes in pharmaceuticals, FMCG, OTC, prescription medicine, veterinary medicine, manforce condoms, acnestar, ring-out, preganews, unwanted 72, unwanted 21 days, gas-o-fast, kabzend, and kaloree1.

Company Headquarters: Illinois, US Founded: 2005 Workforce: ~ 16,600 Company Working: Molson Coors Beverage Company, is primarily a holding company that is engaged in manufacturing, packaging, and selling malt beverage products, such as beer, cider, ales, stouts, and lager. The company has a presence across US, Canada, and UK. The company sales it's products under the name of Molson Canadian, Coors Light, Miller Lite, Blue Moon Belgian White, Carling, and Staropramen to Coors Banquet, Leinenkugel’s Summer Shandy, Blue Moon LightSky, Vizzy, Creemore Springs, Hop Valley and more. The business segment under which the company operates is Americas, and EMEA & APAC. The Americas segment develops, marketing, and sells the brands and other owned and licensed brands in the U.S., Canada, and various countries in the Caribbean, Latin, and South America. The company currently operates nine craft breweries, nine primary breweries, and two container operations. The EMEA&APAC segment is also engaged in the production, marketing, and sales of various brands in Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, the Republic of Ireland, Romania, Serbia, the U.K., various other European countries, and certain countries within the Asia Pacific and Middle East, and Africa. This segment currently operates eleven primary breweries, six craft breweries, and one cidery.

Company Headquarters: Karnataka, India Founded: 1978 Workforce: ~16,545 Company Working: Biocon manufactures and sells generic active pharmaceutical ingredients (APIs). It also provides a variety of branded formulations, complex biologics, and biosimilars like monoclonal antibodies (MAbs), rh-Insulin, and insulin analogues in addition to several active pharmaceutical ingredients (APIs). Additionally, the company provides contract manufacturing, medicine licensing, research, development, and the production of both small and large molecules to pharmaceutical and biotechnology organizations all over the world. In order to develop solutions that meet the various needs of patients around the world, Biocon has invested in cutting-edge technology, major research collaborations, and global manufacturing scale over the years. As an emerging international company, Biocon is meeting patients' needs in more than 100 nations with unique products. It has a production unit and an R&D facility at BioXcell in Malaysia. Furthermore, it has operations in the UK, Ireland, the US, Switzerland, Dubai, and Malaysia.

Company Headquarters: Melbourne, Florida, US Founded: 2019 Workforce: ~47,000 Company Working: L3Harris Technologies, Inc. (L3Harris) is formed by the merger of L3 Technologies Inc. and Harris Corporation. The company provides technology-based solutions to address mission-critical challenges government and commercial customers face in the US and international markets. It operates through three business segments, namely, communication systems, space and intelligence systems, and electronic systems. It designs, develops, and manufactures radio communications products and systems, vision-enhancing products, wireless communications systems, and Internet protocol-based voice and data communications systems. Additionally, L3Harris provides electronic warfare, avionics, command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) solutions for defense and classified customers and mission-critical communication systems for civil and military aviation customers.

Company Headquarters: Schaffhausen, Switzerland Founded: 1941 Workforce: ~ 92,000 Company Working: TE Connectivity is a company that creates connectivity and sensor solutions. Connector systems, terminals and components, sensors, relays, heat shrink tubing, interventional medical components, wire and cable, and antennas are all available from the company. These products and solutions are used in a variety of industries, such as automotive, aerospace, defence, marine, industrial, medical, data and devices, appliances, and energy. It sells products under the brand names Agastat, Ampower, Buchanan, Citec, Cloudsplitter, Deutsch, Entrelec, Faston, Holsworthy, Intercontec, Kilovac, Kissling, and Madison Cable. The company sells its products directly to customers and through third-party distributors. It operates manufacturing and distribution facilities in Asia-Pacific, Europe, the Middle East, Africa, and the Americas.

Company Headquarters: Pennsylvania, United States Founded: 1930 Workforce: ~ 18,500 Company Working: AMETEK is a manufacturer of electronic products. It makes electronic instruments as well as electromechanical devices. Medical materials, motion control systems, sub-assemblies and connectors, electrical cord reels, gauges, titanium alloys, and other products are among the company's offerings. AMETEK also offers UPS systems, power inverters, engine and aircraft condition monitoring systems, and oil and gas production products at the upstream, midstream, and downstream levels. Electronic cable assemblies, heavy vehicle custom instrumentation, polymers, resins, engineered connectors, motors, blowers, and pumps for transportation, and other products are available from the company. Its products are used in the medical, aerospace and defense, power, and oil and gas industries. The company's operations are spread across the Americas, Europe, and Asia.

Company Headquarters: Minnesota, United States Founded: 1902 Workforce: ~90,000 Company Working: The 3M Company is a multinational conglomerate corporation based in the United States. The company was founded as a mining venture, but later diversified into other industries such as healthcare, electronics, and transportation. The name 3M comes from the company's original name, Minnesota Mining and Manufacturing, which reflected its roots in the mining industry. Today, 3M is known for its wide range of products, including consumer goods such as Post-it Notes and Scotch Tape, as well as industrial products such as adhesives, abrasives, and tapes. 3M has operations in more than 70 countries. The company is headquartered in Maplewood, Minnesota, and has been listed on the New York Stock Exchange since 1946. 3M is known for its commitment to innovation and research and has a long history of developing new products and technologies.

Company Headquarters: Sparks, Nevada, US Founded: 1963 Workforce: ~5,000 Company Working: Sierra Nevada Corporation is a provider of electronic aerospace and defense systems. It offers communication, navigation, and air traffic management systems. The company also offers intelligence, reconnaissance, surveillance, command, and control products. It serves customers in the US and other internationals.

Company Headquarters: Seoul, South Korea Founded: 1958 Workforce: ~2,59,915 Estimated Commercial Laundry Revenue- US$ 396.1 Mn Company Working: LG Electronics Inc. is engaged in developing new technology and consumer electronics products. The company has a presence in almost every country worldwide. The company is a leading manufacturer of consumer and commercial products. LG Electronics operates with its four major business segments including Home Appliance & Air Solutions, Home Entertainment, vehicle Components Solutions, and Business Solutions. The Home Appliance & Air Solution segment provides refrigerators, washing machines, vacuum cleaners, and residential and commercial air conditioners. The Home Entertainment segment is involved in providing TVs and digital media products. Under its Vehicle Components Solutions segment the company designs and manufactures automobile parts. The Business Solutions segment specializes in the development of monitors, PCs, information displays, solar panels, and others. The company has manufacturing facilities in Pyeongtaek, Changwon, Gumi, and Incheon in the Republic of Korea. LG Electronics has a presence across North America, Europe, Asia-Pacific, Middle East, and Africa. A few of the affiliated companies working under LG Electronics are LG Electronics Nanjing Vehicle Components Co., Ltd., LG Electronics Algerie SARL, LGEUS Power LLC, and LG Electronics Overseas Trading FZE among others.

Vertex is the world's dominant cystic fibrosis franchise owner and, increasingly, a diversified specialty biotechnology platform. Its economic engine is a near-monopoly in CFTR modulation — five approved medicines treating roughly 95 percent of people with CF in core markets, generating over $11.1 billion of FY2025 revenue at 86 percent gross margin and effectively no branded competition until the late 2030s. Around that annuity, management has assembled four additional growth pillars: hematology (CASGEVY, the first approved CRISPR/Cas9 therapy), acute pain (JOURNAVX, the first new non-opioid analgesic mechanism in decades), nephrology (povetacicept, PDUFA 30 November 2026; inaxaplin behind it), and — following the $10.0 billion Crinetics acquisition completed 1 September 2026 — rare endocrinology. Vertex is unusual among large-cap biotechs in combining double-digit organic revenue growth, 40 percent-plus non-GAAP operating margins, a net cash balance sheet, and no dividend. The central investment question is whether the non-CF pillars scale before CF growth mathematically decelerates. | Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Employees (approx., headcount) | 5000 | 5800 | 6400 | FY2025 is verified from the FY2025 Form 10-K. --- ### The company's own characterisation From the FY2025 Form 10-K, Item 1: Vertex describes itself as "a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets." It states approved medicines for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, with mid- and late-stage clinical programmes across IgA nephropathy, APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, autosomal dominant polycystic kidney disease and myotonic dystrophy type 1. The stated core strategy is "to discover, develop, and commercialize innovative medicines by combining transformative advances in the understanding of human disease and the science of therapeutics." Management identifies five selection filters for programmes: disease areas with known causal human biology; targets validated by causal human biology; predictive lab assays and clinical biomarkers; potential for transformative benefit regardless of modality; and an efficient path to registration and approval. The company repeatedly uses the term "serial innovation" — advancing multiple compounds per target so that first-in-class assets are followed by internally generated best-in-class successors. ### Independent characterisation Vertex is best understood as a causal-biology franchise operator rather than a conventional diversified pharmaceutical company. Three structural features distinguish it: **A single-product-family concentration with monopoly economics.** In FY2025, TRIKAFTA/KAFTRIO alone contributed $10.31 billion, or 85.9 percent of total revenue. Adding ALYFTREK ($837.8 million) and the legacy CF portfolio ($644.7 million) puts cystic fibrosis at $11.80 billion, or 98.3 percent of total revenue. No competitor markets an approved CFTR modulator. Vertex is therefore not competing on price or share within its core market; it is competing against the natural ceiling of a fixed genetic patient population (approximately 112,000 people in target markets, of whom roughly three quarters are already treated). **A specialty, not primary-care, commercial model.** The company sells primarily to a limited number of specialty pharmacies and specialty distributors, plus certain major U.S. wholesalers; outside the U.S. it sells largely through distributors, retail pharmacies and government-owned or supported hospitals and clinics. CASGEVY is sold in certain markets directly to authorised treatment centres. This model supports very low SG&A intensity relative to peers — SG&A was 14.6 percent of revenue in FY2025 even in a triple-launch year — and management explicitly reiterates a "commitment to specialty model" in investor materials. **A modality-agnostic R&D engine.** Vertex has now delivered approved products across small molecules (CFTR modulators, JOURNAVX), ex vivo CRISPR/Cas9 gene editing (CASGEVY), and is in pivotal development with a biologic (povetacicept, a BAFF/APRIL dual inhibitor) and a stem cell-derived cell therapy (zimislecel). Post-Crinetics it adds a GPCR-focused small molecule endocrinology platform. ### Revenue model Vertex's revenue is essentially 100 percent product revenue. In FY2025, product revenues net were $11,970.6 million of $12,001.3 million total revenue; the residual $30.7 million of "other revenues" reflects out-licensing consideration (principally the 2025 Zai Lab and Ono povetacicept agreements for Asian territories). There is no meaningful service, subscription or device revenue. Royalty and milestone income is de minimis on the inbound side and Vertex is a net payer of royalties — notably to the Cystic Fibrosis Foundation under the 2004 CFF Agreement (tiered single-digit to sub-teens royalties on ivacaftor, lumacaftor and tezacaftor; low-to-mid single digits on elexacaftor; no royalty on compounds first synthesised and tested on or after 1 September 2016, which importantly means vanzacaftor and deutivacaftor in ALYFTREK carry lower royalty burden). CASGEVY is economically distinct: under the amended and restated joint development and commercialisation agreement with CRISPR Therapeutics AG, net profits and losses are allocated 60 percent to Vertex and 40 percent to CRISPR, with Vertex leading global development, manufacturing and commercialisation. ### Value chain position Vertex occupies the discovery-through-commercialisation span but is deliberately asset-light in manufacturing. It maintains internal small molecule manufacturing in Boston (used for clinical and certain commercial TRIKAFTA/KAFTRIO steps) and internal cell therapy manufacturing capability in the Boston area, but relies on a global third-party network — including contract manufacturers based in China — for the majority of commercial supply, with second sources maintained for the vast majority of commercial products including active ingredients, drug product and finished dosage packaging. A strategic agreement with Lonza supports T1D cell therapy manufacture. ### Customers and end-markets Direct customers: specialty pharmacies, specialty distributors, wholesalers, hospitals, clinics, authorised treatment centres, and government-owned or supported purchasers outside the U.S. Economic customers: national payors and reimbursement authorities (NHS England, AIFA, G-BA/GKV, HAS, PBAC, pCPA), U.S. commercial payors, the three national U.S. pharmacy benefit managers, state Medicaid programmes, Medicare Part D plans, and Gulf state health ministries. End-markets served as of the report date: cystic fibrosis; severe sickle cell disease; transfusion-dependent beta thalassemia; moderate-to-severe acute pain; and — from 1 September 2026 — acromegaly (PALSONIFY). Near-term addressable: IgA nephropathy (PDUFA 30 November 2026).

Company Headquarter: France Founded: 1963 Workforce: ~38000 employees Company Working: Kering SA (previously known as Pinault-Printemps-Redoute or PPR) is a French multinational luxury goods company that designs, manufactures, and sells apparel, accessories, and other luxury products. Kering owns several well-known luxury brands, including Gucci, Yves Saint Laurent, Bottega Veneta, Balenciaga, Alexander McQueen, Brioni, Boucheron, Pomellato, and Qeelin. The company operates in more than 120 countries and has a workforce of over 38,000+ employees. In addition to its luxury fashion brands, Kering also has interests in the sports and lifestyle sector, owning Puma, Cobra Golf, and Volcom.

Company Headquarters: Milan, Italy Founded: 1975 Workforce: ~9,064 Company Working: Giorgio Armani's company deals in the fashion and luxury products group in the world. The company has 12 production plants and more than 2,704 boutiques in 60 countries around the world. Giorgio Armani specializes in designing, manufacturing, distributing, and retailing fashion and lifestyle products including accessories, apparel, watches, eyewear, home interiors, jewelry, fragrances, and cosmetics under a range of brands such as Emporio Armani, and Giorgio Armani.

Advanced Enzyme Technologies is India's largest enzyme company and one of the few listed, research-led, vertically integrated enzyme and probiotic manufacturers globally. It develops, ferments, formulates and markets more than 400 proprietary products built from over 68 enzymes and probiotic strains, serving four verticals: human nutrition (its dominant franchise, about 63% of FY2026 revenue), animal nutrition, industrial bio-processing (food and non-food), and specialised contract manufacturing. Its economic engine is the high-value, low-volume niche of therapeutic and nutraceutical enzymes — digestive and proteolytic enzymes, and the anti-inflammatory enzyme serratiopeptidase — sold B2B to supplement brands and pharma formulators in the United States and India, with a nascent B2C brand (Wellfa). FY2026 delivered record revenue of INR 7,458M (+17%), EBITDA of INR 2,291M (31% margin) and PAT of INR 1,736M (+30%), on a fortress balance sheet with net cash of roughly 41% of book equity. --- **Company's own description.** In its Integrated Annual Report 2025-26 (themed "Scaling Innovation, Committed to Sustainability") the company describes itself as a research-driven organisation engaged in the research, development, manufacturing and marketing of proprietary enzyme products and probiotics, with leadership in B2B enzyme supply and specialised enzyme expertise that creates significant entry barriers. It frames its mission through the long-standing tagline "Where ENZYME is Life" and its vision of becoming the leading enzyme-based value provider to consumers and bio-processing industries, using enzymes to replace chemicals and improve process efficiency. **Independent characterisation.** AETL is best understood as a specialty biologics ingredient manufacturer rather than an industrial-enzyme commodity supplier. Unlike Novonesis, dsm-firmenich or IFF — which dominate high-volume detergent, starch, ethanol and baking enzymes — AETL earns the bulk of its revenue and nearly all of its excess margin from nutraceutical and pharmaceutical-grade enzymes where regulatory dossiers, strain libraries, formulation know-how and long customer qualification cycles matter more than fermentation scale. The US subsidiary (Advanced Enzymes USA, which includes Specialty Enzymes & Biotechnologies) is the commercial spearhead into the American dietary-supplement market and earned PAT of INR 784M on revenue of INR 2,122M in FY2026 — a net margin near 37% (Annual Report FY2026 subsidiary disclosures). **Business model.** Overwhelmingly product sales (B2B ingredients and finished formulations), with small contributions from contract manufacturing services (Specialized Manufacturing vertical: effervescent formats, pharma/nutraceutical CDMO via SciTech Specialities, Saignesh, JC Biotech) and B2C consumer sales (Wellfa). There is no material licensing, subscription or royalty revenue disclosed. **Value-chain position.** AETL operates across strain development and enzyme engineering (R&D in India, US and Germany via evoxx), submerged and solid-state fermentation, downstream processing, blending/formulation and, increasingly, finished dosage forms. It sits one or two steps upstream of the consumer: its typical customer is a supplement brand or formulator that buys enzyme blends to market under its own label. **Customer types and end markets.** **Concentration.** Historically the top 10 customers contributed about 28% of revenue (FY2022, per ICICI Securities result update, Q4 FY22) and the anti-inflammatory enzyme (serratiopeptidase) was the single largest product at about INR 1,039M in FY2022 (same source). Updated product-level concentration for FY2026 is not publicly disclosed.

Company Headquarters: Netherlands Founded: 1911 Workforce: ~ 32,800 Company Working: AkzoNobel N.V. is a Dutch multinational chemical company headquartered in Amsterdam, Netherlands. It is the world's largest producer of paints and coatings, and it also produces a range of other chemicals, including mining chemicals. The company offers its products to aerospace, automotive, consumer goods, oil and gas, transportation, buildings, and infrastructure market. It operates in over 150 countries across the Americas, Asia pacific, Europe, the Middle East and Africa. In the mining sector, AkzoNobel provides specialized chemical solutions that contribute to various stages of mineral processing and extraction. The company offers a range of products, including flotation reagents, solvent extractants, dispersants, flocculants, and other chemicals that enhance the efficiency of mineral separation, extraction, and purification processes. AkzoNobel's mining chemicals are designed to address specific challenges faced by mining operations, such as improving recovery rates, reducing water and energy consumption, and minimizing environmental impact.

Company Headquarters: Tokyo, Japan Founded: 1907 Workforce: ~30,538 Company Working: Kirin Holdings Company, Limited. is among one of the manufacturers, developers, and marketers of non-alcoholic, and alcoholic beverages. The company also offers pharmaceutical products across the globe. Kirin Lager is the oldest beer brand of the company and has been brewed since 1888. Kirin Holdings Company, Limited. is formed based on the Japanese traditions of breweries that are retaining the application of hops and malted grains that are imported from Germany and also employ brewers from Germany to oversee the production process. The major product portfolio of the company is beer, spirits, wines, seltzer, new genre, chu-hi, hopposhu, kombucha, whiskey, tea, black tea, coffee, carbonated beverages, vegetable/fruit beverages, health/sports drinks, ionized natural water, and other pharmaceutical products. Kirin Holdings Company, Limited. markets its products under the brand names such as Kirin Tanrei Green Label, Kirin Nama-cha, Kirin Hyoketsu, Kirin Mets COLA, Kirin Fire, Kirin Gogo-no-Kocha, Kirin Sekai-no-Kitchen-Kara, Kirin Nodogoshi Nama, Kirin Ichiban, Baden, Kirin FREE, Berri, Chateau Mercian, and San Miguel Pale Pilsen. Moreover, the company has diversified business operations in both the Americas and Europe along with Asia Pacific.

Red Bull GmbH is the world's most valuable single-brand beverage franchise and the originator of the modern Western energy-drink category. It is not, in operational terms, a beverage manufacturer: it is a brand, marketing and route-to-market company that outsources filling and canning to long-standing partners (Rauch Fruchtsäfte, Ball Corporation) and reinvests an unusually large share of gross profit into owned sports properties and owned media rather than conventional advertising. That structure produces a balance sheet dominated by working capital, brand and sports assets rather than plant, and a stated position of zero financial debt with growth funded entirely from operating cash flow. FY2025 was the company's strongest year since the post-pandemic rebound: EUR 12.196 billion of turnover, 13.969 billion cans, and record operating profit. The franchise now faces its first genuine structural tests — a European Commission abuse-of-dominance investigation, sugar-free and functional challengers eroding category share, and a post-founder governance model still being proved. --- **The company's own characterisation.** Red Bull's published company profile describes a business founded on a single product idea — a functional beverage containing caffeine, taurine, B-group vitamins, sugars and water, sold in a 250ml slim aluminium can — brought from Thailand to Europe by Dietrich Mateschitz in partnership with Chaleo Yoovidhya, reformulated for Western palates, and launched in Austria in 1987. The company frames itself around the phrase "giving wiiings to people and ideas," and describes its activity as spanning beverages, sports teams, athlete support, events, and media production. It states that in FY2025 it sold 13.969 billion cans in 178 countries, generating EUR 12.196 billion of group turnover with 21,924 employees. **Independent characterisation.** Red Bull is best understood as three interlocking businesses operating under one unlisted holding company. *First, the beverage business.* This is the profit engine and the source of essentially all group turnover growth. Its economics are unusual for a consumer packaged goods company. Red Bull does not own its filling plants; production is contracted to Rauch Fruchtsäfte, historically in Austria (Nüziders) and Switzerland, and increasingly in "wall-to-wall" integrated campuses where Ball Corporation manufactures the aluminium can metres from where Rauch fills it and Red Bull's own distribution arm warehouses it. The Glendale, Arizona campus (operational 2021) and the Concord, North Carolina campus (under construction, USD 1.7 billion, operations targeted 2028) are the two integrated US examples. The consequence is a capital-light manufacturing model with an unusually high share of value captured in brand, formulation IP and route-to-market, and a cost structure exposed to aluminium and contract-filling economics rather than owned-plant depreciation. *Second, the route-to-market business.* In its most important markets Red Bull runs its own distribution rather than relying on Coca-Cola or Pepsi bottler systems — Red Bull Distribution Company in the United States operates roughly 150 warehouses nationally (CRU Aluminum Market Update, September 2025). This is the structural difference from Monster, which rides the Coca-Cola bottler network. Owning distribution gives Red Bull cold-vault control, chilled-cooler placement (Red Bull-branded coolers are a deliberate asset class) and category-captain positions in retail — the last of which is now the subject of the European Commission's investigation. *Third, the sports and media business.* Red Bull owns or holds stakes in two Formula 1 teams, an F1 power-unit manufacturer, seven-plus football clubs, ice hockey clubs, a WorldTour cycling team, an English rugby club, esports organisations, a race circuit, an aircraft fleet, a television network (ServusTV), a record label, a magazine and a content studio. Management treats these not as diversification but as owned marketing inventory: rather than buying media, Red Bull manufactures the events and the content that carry the brand. Sponsorship and athlete payments alone exceeded EUR 1 billion for the first time in 2022 (Bloomberg, citing company filings) and the company has not disclosed a figure since. **Revenue model.** Effectively 100% product revenue from the sale of physical beverage units through wholesale and direct-store-delivery channels. There is no subscription revenue, no meaningful licensing line disclosed, and media and sports revenues (broadcast, prize money, transfer fees, sponsorship inbound) are not separately reported and are widely understood to be net cost centres funded by the beverage business. Red Bull does license the brand in limited categories (apparel, some regional bottling arrangements) but no licensing revenue figure is publicly disclosed. **Value chain position.** Brand owner and category orchestrator. Upstream: contract manufacture (Rauch), packaging (Ball, Ardagh, Crown in some geographies), ingredient supply (caffeine, taurine, sweeteners, Alpine water sourced local to fill sites). Downstream: own distribution in core markets, third-party distributors elsewhere, off-trade (supermarkets, convenience, forecourts — approximately 86% of global energy-drink revenue per Grand View Research 2025) and on-trade (bars, clubs, gyms). **Customer types and end-markets.** Grocery and convenience retail chains, petrol-station forecourt operators, wholesalers and cash-and-carry, on-premise hospitality, e-commerce, workplace and gym channels, and military/institutional. End-consumer skew is 18–34, with Gen Z accounting for roughly 28% of global energy-drink consumption volume (ZipDo aggregation of industry data, 2026).

Company Headquarters: Paris, France Founded: 1910 Workforce: ~27,018 Company Working: Chanel S.A. (Chanel) is involved in developing, manufacturing, and distributing luxury products. The company offers a broad range of products, including leather goods, ready-to-wear, eyewear, fashion accessories, fragrances, skincare, makeup, jewelry, and watches. Chanel provides its products in several countries in regions such as Europe, Asia-Pacific, and the Americas

Company Headquarters: Tennessee, US Founded: 1917 Workforce: ~ 4,964 Company Working: Mueller Industries specializes in copper and copper alloy manufacturing and producing goods from steel, aluminum, and plastics. It offers copper tube and fittings, aluminum and brass forgings, brass and copper alloy rods and bars, aluminum and copper impact extrusions, refrigeration valves and fittings, fabricated tubular products, and plastic fittings and valves. It has a network of operations in North America, Europe, Asia-Pacific, and the Middle East. It supplies products into sectors such as building construction, defense, appliance, energy, and automotive.

Company Headquarters: Nürnberg, Bayern, Germany Founded: 1902 Workforce: 3,327 Company Working: Diehl Metall Stiftung & Co KG operates as a subsidiary of Diehl Stiftung & Co KG. It manufactures semi-finished products, high-precision stamped parts, forgings, and metal-plastic compound systems for electronic and other applications. It offers copper alloys, brass alloys, cell contact system, metal forming parts, pin fin heat sinks, synchronizer rings, press fir zones, and strips and wires. It serves customers in the automotive, heating, plumbing, and electronic industries worldwide. It has its operating locations in Europe, Asia, South America, and the US.

Company Headquarters: Bridgewater, US Founded: 2011 Workforce: ~ 40,039 Company Working: Vyne Therapeutics Inc., formerly known Menlo Therapeutics, focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions such as prurigo nodularis and psoriasis. It has a sales presence in the US and Israel.

Company Headquarters: Ballerup, Copenhagen, Denmark Founded: 1908 Workforce: ~5,820 Company Working: LEO Pharma A/S (LEO Pharma) is a global dermatology company. The company develops and markets products for dermatology, bone remodeling thrombosis, and coagulation. It provides products in multiple delivery systems such as topical, injections, and tablets. It operates through six major business segments, including Psoriasis, Eczema /Skin infection, Thrombosis, Acne/Rosacea, Actinic keratosis, and CMOs/Others. The company has a presence in more than 130 countries globally.

Company Headquarters: Taiwan Founded: 1987 Workforce: ~51,000 Company Working: Taiwan Semiconductor Manufacturing Company Limited (TSMC) is one of the world's leading semiconductor foundries. The company is engaged in developing, selling, packaging, testing, and computer-aided designing of integrated circuits (ICs) and other semiconductor devices and manufacturing masks. The company provides a wide range of integrated semiconductor foundry services, including the most advanced process technologies, leading specialty technologies, the most comprehensive design ecosystem support, excellent manufacturing productivity and quality, advanced mask technologies, 3DFabricTM advanced packaging, and silicon stacking technologies, to meet a growing variety of customer needs. The company deployed 281 diverse process technologies and created 11,617 items for 510 clients in 2020 by providing the broadest range of advanced, specialty, and advanced packaging technology services. The corporation is active in Asia, Europe, North America, and other parts of the world.